Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze

The most recent news, dated October 14, 2025, announces that Vireo Growth Inc. has closed its acquisition of senior secured convertible notes of Medicine Man Technologies Inc. (dba Schwazze). Vireo acquired notes with a face value (principal and interest) of approximately $91 million for a total consideration of $62 million. This payment was made by issuing 114,807,815 subordinate voting shares of Vireo, implying a deemed price of ~$0.54 per share.

Crucially, the news outlines a comprehensive restructuring plan for Schwazze, whose notes were in default. Key elements of the plan include: * A Restructuring Support Agreement (RSA) between Vireo and Schwazze. * The creation of a new entity ("NewCo"), which will be majority-owned by Vireo. * NewCo will acquire the majority of Schwazze's assets through a "credit bid" at an auction. This means Vireo will use the face value of the debt it now holds to purchase the assets. * Following the asset sale, Schwazze's remaining operations will be liquidated. * This transaction effectively allows Vireo to take control of Schwazze's significant operational footprint, which includes 63 dispensaries and 10 manufacturing facilities across Colorado and New Mexico.

This transaction is a game-changer for Vireo. It is not a standard acquisition but a sophisticated distressed-to-control strategy. By purchasing defaulted debt at a 32% discount to its face value and then using that debt's full value to acquire the underlying assets, Vireo is executing a highly accretive maneuver.

Positive Impacts: * Massive Expansion: The deal dramatically increases Vireo's scale, adding a large, established retail and manufacturing footprint in two states. * Favorable Valuation: Acquiring these assets for an effective price of $62 million in stock is likely a steep discount to what they would cost in a traditional M&A transaction, especially given the distressed nature of the seller. * Strategic Use of Equity: The acquisition was funded with equity, preserving Vireo's cash for operational needs and integrating the new assets. * Control: The credit bid mechanism gives Vireo significant control over the acquisition process, allowing it to acquire the core operating assets while leaving unwanted liabilities behind with the shell of Schwazze to be liquidated.

Negative Impacts & Risks: * Massive Dilution: The issuance of ~115 million new shares is highly dilutive to existing shareholders. The future performance of the stock will heavily depend on whether the value generated from the acquired assets outweighs this dilution. * Integration Risk: This is the most significant risk. Integrating 63 dispensaries and 10 manufacturing facilities is a monumental operational challenge. Failure to integrate efficiently could destroy the value proposition of the deal. * Distressed Asset Quality: Schwazze's assets are being acquired out of a restructuring because the company defaulted on its debt. The underlying operations may be unprofitable, inefficient, or require substantial capital investment to turn around. Vireo is not just buying stores; it is buying Schwazze's problems. * Share Overhang: The recipients of the ~115 million shares (the former noteholders) may decide to sell their position, creating a significant overhang on the stock price. Their cost basis is $0.54 per share, providing a strong incentive to sell at current levels near $1.00.

In context, the news from October 14 confirms the plan first announced on October 2. The stock price reacted very positively to the initial announcement, rising from the low $0.80s to nearly $1.00, indicating the market views this aggressive expansion favorably despite the risks. The closing of the deal solidifies this transformative path for the company. The cleverness of the deal structure is a strong positive, but the operational risks ahead cannot be overstated.

Vireo Growth Inc. is a U.S.-based cannabis company. While its prior operations are not detailed, it is now clear that its flagship project is the acquisition and integration of the Schwazze assets. This move positions the company as an aggressive consolidator in the cannabis industry, with a new, significant footprint in Colorado and New Mexico.